<DOC>
	<DOCNO>NCT01367756</DOCNO>
	<brief_summary>This randomize , double-blind , parallel-arm study ass safety tolerability RO4995819 combination citalopram healthy volunteer . Subjects receive citalopram orally Days 1-9 randomized receive either RO4995819 orally placebo combination citalopram Days 10-16 . Safety follow-up Day 58 .</brief_summary>
	<brief_title>A Study RO4995819 Combination With Citalopram Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Adult healthy male female subject , 18 65 year age inclusive ( healthy status define absence evidence active chronic disease ) Body mass index ( BMI ) 18.0 30.0 kg/m2 inclusive Female subject either surgically sterile postmenopausal must commit use barrier form contraception addition either intrauterine device hormonal contraception least 5 month last dose study drug Male subject must use barrier method contraception throughout study 5 month last dose study drug ( applies also surgically sterilized male ) Willing participate clinical trial investigational drug least 5 month follow last dose study drug Pregnant lactating female Suspicion regular consumption drug abuse positive test alcohol Day 2 Hepatitis B , hepatitis C HIV infection Smokers &gt; 5 cigarette equivalent tobacco intake per day Any confirm allergic reaction drug , multiple allergy ( nonactive hay fever acceptable ) Participation investigational drug device study within 3 month prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>